SB05 is a paclitaxel component combined with neutral and positive lipids. Due to the characteristics of targeting the blood supply of tumors, it is expected to inhibit tumor growths. The clinical trials on pancreatic cancer and triple-negative breast cancer have been approved to move forward into phase III by Food and Drug Administration (FDA) and Taiwan FDA.
We are pleased to share that SynCore Biotechnology (SynCoreBio) will attend at American Society of Clinical Oncology, June 1-5, 2018 Chicago, Illinois, USA. (https://am.asco.org/)
SynCore Biotechnology Co., Ltd.